MSTN and pulmonary arterial hypertension: Notably, Sotatercept, a fusion protein that acts as a ligand trap for TGF-β signaling members approved by the FDA in March 2024, induced a greater improvement in exercise capacity of PAH patients by suppressing the GDF8/ACTIVIN A-activated TGF-β signaling [77].